Insider Trading June 12, 2026 06:41 PM

Intuitive Surgical Executive Sells Shares Amidst Operational Updates and Valuation Debates

EVP Mark Brosius executes sales under pre-arranged plan as company advances da Vinci 5 enhancements and leadership structure.

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
ISRG

Intuitive Surgical Inc. (NASDAQ: ISRG) Executive Vice President and Chief Manufacturing and Supply Chain Officer Mark Brosius recently executed the sale of 48 shares of the company's common stock. The transactions, totaling $19,832, were conducted on June 11 and June 12, 2026. These sales occurred at prices ranging from $412.16 to $414.13 per share, which align closely with the stock's current trading price of $411.06. The timing of these sales is notable as Intuitive Surgical's shares are currently trading near their 52-week low of $396.68, representing a significant 27% decline year-to-date. Despite this downward price action, InvestingPro analysis suggests that the stock may be undervalued based on Fair Value metrics. The sales were facilitated under a Rule 10b5-1 trading plan, which is scheduled to expire on February 14, 2027. Following these transactions, Brosius retains direct ownership of 1,406 shares of Intuitive Surgical common stock.

Intuitive Surgical Executive Sells Shares Amidst Operational Updates and Valuation Debates
ISRG
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Intuitive Surgical EVP Mark Brosius sold 48 shares totaling $19,832 on June 11 and June 12, 2026, under a Rule 10b5-1 plan expiring February 14, 2027.
  • The company is advancing its da Vinci 5 robotic surgical system with over 100 enhancements, including Intuitive Telepresence, available in the U.S. starting in June.
  • Piper Sandler maintains an Overweight rating on ISRG with a $580 price target, citing first-quarter results that exceeded consensus estimates for revenue and earnings.

Mark Brosius, serving as the Executive Vice President and Chief Manufacturing and Supply Chain Officer at Intuitive Surgical Inc. (NASDAQ: ISRG), has completed the sale of 48 shares of the company's common equity. The transactions were executed on June 11 and June 12, 2026, resulting in a combined sale value of $19,832. The shares were divested at prices ranging between $412.16 and $414.13 per share. These execution prices are situated in close proximity to the stock's current market price of $411.06. The execution of these sales occurs as Intuitive Surgical shares are trading near their 52-week low of $396.68. This price level reflects a substantial 27% decline in the stock's value year-to-date. According to InvestingPro analysis, the stock appears undervalued based on Fair Value metrics. The transactions were conducted in accordance with a Rule 10b5-1 trading plan, which is set to expire on February 14, 2027. Following these sales, Mr. Brosius directly owns 1,406 shares of Intuitive Surgical common stock.

In addition to the insider transaction, Intuitive Surgical has announced several operational updates and personnel changes. The company reported enhancements to its da Vinci 5 robotic surgical system, incorporating over 100 improvements and extended use capabilities for its instruments. These updates are available in the U.S. starting in June and aim to improve features like Intuitive Telepresence, which allows remote observation of procedures. Piper Sandler has maintained an Overweight rating on Intuitive Surgical, adjusting its price target to $580, based on the company's first-quarter results that surpassed consensus estimates for both revenue and earnings. Piper Sandler's recent field check with a major U.S. healthcare system supported their positive outlook on Intuitive Surgical, particularly regarding the da Vinci system.

In management changes, Intuitive Surgical announced the promotion of Taylor Patton to Chief Commercial and Marketing Officer, effective July 1. Patton will replace Henry Charlton, who will transition to Senior Vice President of Global Business Operations. These developments reflect ongoing progress and strategic adjustments within the company.

Risks

  • The stock is trading near its 52-week low of $396.68, down 27% year-to-date, indicating potential valuation pressure in the healthcare technology sector.
  • The execution of insider sales, while under a pre-arranged plan, may be monitored by investors assessing management confidence amid the year-to-date price decline.

More from Insider Trading

CoreWeave Executive Brian Venturo Disposes of $7.45 Million in Class A Shares Amid Strategic Debt Issuance Jun 12, 2026 Dorian LPG Director Christina Tan Disposes of $251,608 in Company Stock Jun 12, 2026 Silver Lake Affiliates and Dell Director Egon Durban Execute $18.5 Million Stock Sale Jun 12, 2026 Microsoft Executive Takeshi Numoto Executes $1.81 Million Stock Sale Jun 12, 2026 Slide Insurance CRO Liquidates $234,712 in Stock Under Pre-Arranged Plan Jun 12, 2026